Patents Assigned to Cancer Institute
-
Publication number: 20240115721Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Publication number: 20240115720Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.Type: ApplicationFiled: January 13, 2022Publication date: April 11, 2024Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITEDInventors: John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
-
Patent number: 11952432Abstract: The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.Type: GrantFiled: February 7, 2019Date of Patent: April 9, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Rida Mourtada, Henry D. Herce
-
Patent number: 11944625Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.Type: GrantFiled: February 12, 2021Date of Patent: April 2, 2024Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
-
Patent number: 11945816Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.Type: GrantFiled: October 20, 2021Date of Patent: April 2, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
-
Patent number: 11945846Abstract: Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.Type: GrantFiled: March 9, 2020Date of Patent: April 2, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Rida Mourtada
-
Patent number: 11946105Abstract: Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.Type: GrantFiled: June 11, 2021Date of Patent: April 2, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Matthew Meyerson, Aleksandar Kostic
-
Publication number: 20240101559Abstract: The present disclosure provides compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK) (e.g., Janus kinase 2 (JAK2)) and/or cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 11 (CDK11)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).Type: ApplicationFiled: October 2, 2020Publication date: March 28, 2024Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Tinghu Zhang, Yao Liu, David Weinstock, Loretta Sze-Mun Li
-
Publication number: 20240091213Abstract: Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.Type: ApplicationFiled: May 23, 2023Publication date: March 21, 2024Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITALInventors: Nathanael S. Gray, Stephen J. Haggarty, Quan Cai, Tinghu Zhang, Maria Catarina Telo Baptista Lima da Silva, Fleur M. Ferguson
-
Publication number: 20240093310Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.Type: ApplicationFiled: September 11, 2023Publication date: March 21, 2024Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
-
Publication number: 20240094208Abstract: An isolated nucleic acid molecule encoding a mutant MEK1 protein having MEK1 activity is disclosed. The mutant MEK1 protein comprises an amino acid substitution at position 121 of wild-type MEK1 shown in SEQ ID NO: 2. The amino acid substitution confers resistance to one or more RAF or MEK inhibitors on a cell expressing the mutant MEK1 protein.Type: ApplicationFiled: September 6, 2023Publication date: March 21, 2024Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Levi A. Garraway, Caroline Emery, Nikhil Wagle
-
Publication number: 20240092735Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.Type: ApplicationFiled: November 7, 2023Publication date: March 21, 2024Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Michael Erb, Jun Qi
-
Patent number: 11932625Abstract: The present invention provides novel compounds of Formulae (I?) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.Type: GrantFiled: March 7, 2022Date of Patent: March 19, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Baishan Jiang, Nicholas Paul Kwiatkowski
-
Publication number: 20240083847Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.Type: ApplicationFiled: September 29, 2023Publication date: March 14, 2024Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Tinghu Zhang, Tyler Faust, Katherine Donovan, Quan Cai, Zhengnian Li
-
Patent number: 11926874Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.Type: GrantFiled: August 2, 2019Date of Patent: March 12, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Peter Hammerman, Matthew Meyerson, Chandra Pedamallu, Sam Freeman
-
Publication number: 20240067641Abstract: The application relates to a compound of Formula (I): which modulates the activity of TRIM33, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which TRIM33 plays a role.Type: ApplicationFiled: June 28, 2023Publication date: February 29, 2024Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Jun Qi, Cheng-kui Pei
-
Patent number: 11915828Abstract: A method for autonomously identifying symptom terms in free running text data includes the acts of defining a plurality of symptom terms associated with a particular pathology or therapeutic substance or procedure, labeling in a text data set any defined symptom terms and associating a tag indicating any of a positive, negative, or other status with relation to the labeled symptom term, and processing with a natural language processing algorithm multiple different subsets of the text data containing labeled symptom terms to identify a frequency of occurrence of a symptom term and to improve identification accuracy.Type: GrantFiled: June 3, 2020Date of Patent: February 27, 2024Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventor: Charlotta Lindvall
-
Patent number: 11908590Abstract: A shielding apparatus for a radioisotope production system is provided. The shielding apparatus is capable of being retro-fitted to the housing of preinstalled radioisotope production systems. The shielding apparatus comprises a plurality of shield layers removably stacked on top of a base that is mounted to the top of the housing via spacers defining space or air gap between the base and housing. The shield layers and base are positioned above and extending between the interface between moveable shields and a moveable base of the radioisotope production system, such that the shielding apparatus is positioned within the trajectory of a radioisotope production system beam.Type: GrantFiled: November 19, 2019Date of Patent: February 20, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Erol Bars
-
Patent number: 11904310Abstract: The present invention generally relates to a controlled fluidic device to develop spatially complex environments to enhance the rate of evolution in cell populations. The method further provides an enhanced understanding in the emergence, for example, drug resistance during cancer chemotherapy.Type: GrantFiled: October 28, 2016Date of Patent: February 20, 2024Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Anindita Basu, Christopher B. Ford, Aviv Regev, David A. Weitz, Asaf Rotem, Kevin Struhl
-
Publication number: 20240052428Abstract: The invention provides compositions and methods useful in characterizing and/or treating classical Hodgkin's Lymphoma and/or primary mediastinal B-cell lymphoma (PMBL). In embodiments, the characterization is carried out using a biological sample comprising circulating tumor DNA (ctDNA) from a subject.Type: ApplicationFiled: September 15, 2023Publication date: February 15, 2024Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Margaret SHIPP, Gad GETZ, Bjoern CHAPUY, Kirsty WIENAND, Donald STEWART, Andrew DUNFORD, Mark MURAKAMI, Lee LAWTON